Skip to main content
FTV logo

FTV · Fortive Corp

Track FTV — free
$57.26 +0.84 (+1.49%) At close · Oct 9
Market Cap
$17.46B
Shares
304.86M
Volume · Oct 9 1.58M Avg daily vol (3M) 2.41M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$57.26 Open$57.01 Day$56.43–57.29 52W close$47.80–64.09 Avg vol 30d2.3M Short int17.2M · 5.6% float · 7.9d Short vol71% Last earningsOct 28, 2026 DataJan 2020–Oct 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Oct 28, 2026 Scheduled · in 3 wks
filed Jul 29, 2026
call held Jul 29, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4.24B
Trailing 12 months
Net income (TTM)
$543.70M
Trailing 12 months
Revenue growth YoY
+7.7%
Year over year
Operating margin
17.6%
Trailing 12 months
P / E (TTM)
33.8
Trailing earnings · reciprocal yield 3.0%
FCF yield
5.5%
TTM · current market cap
Return on invested capital
7.1%
Trailing 12 months
Net cash
−$3.13B
Latest balance sheet
Dividend yield
0.4%
Trailing 12 months
Shares change YoY
-9.2%
Year over year · fewer shares
Price change (1Y)
+13.2%
Trailing year
Short interest
5.6%
Latest settlement · 7.9 days to cover
View all 115 metrics

AI Brief

Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26

TL;DR. Fortive delivered Q2 core revenue growth of 6.7%, adjusted EBITDA growth of 12%, and adjusted EPS growth of 28%, and raised full-year 2026 adjusted EPS guidance to $2.95–$3.05 while continuing aggressive share repurchases (~$200M in Q2, ~$2B over the last four quarters).

Bullish
  • + Core revenue accelerated to 6.7% and full-year core growth guidance raised to ~4% (from 2–3%).
  • + Raised full-year 2026 adjusted EPS guidance to $2.95–$3.05.
  • + Adjusted EPS grew 28% to $0.74 and adjusted EBITDA margin expanded ~110 bps to 29.5%.
  • + Continued aggressive capital return with ~$200M of Q2 buybacks and ~$2B (~11% of shares) repurchased over the last four quarters.
  • + Intelligent Operating Solutions core revenue grew 7.4% with adjusted EBITDA margin up ~100 bps to 34.9%.
  • + Free cash flow of $271M in Q2; trailing-twelve-month free cash flow topped $1B with conversion well above 100%.
Bearish
  • − Adjusted gross margin contracted ~100 bps to 63% on product mix shift toward lower-margin products.
  • − Advanced Healthcare Solutions adjusted EBITDA margin contracted ~80 bps to 26.1% on mix and growth investments.
  • − EMEA revenue declined modestly due to macroeconomic and geopolitical softness.
  • − Q3 adjusted EBITDA margin expected slightly below Q2 levels on tougher comp and growth investments.
  • − Q4 faces ~150 bps core growth headwind and $15–$20M revenue headwind from four fewer selling days.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Very Bearish Fundamentals Strong Quant / Vol Very Low
Market backdrop VIX 14.8 · calm Equity put/call 0.56
Technical
price trend
Neutral
50 / 200-day cross Death cross
Price vs 200-day avg −2%
below
Price vs 50-day avg −1%
below
RSI (14) 53
neutral
MACD trend Positive
52-week position 58%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Neutral
1-month return +5%
trailing
6-month return −6%
trailing
YTD return +4%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Very Bearish
Trend (MA cross) Death cross
50d $58 › 200d $58 — 200d above 50d
Institutional flow Distributing
39 of 811 funds reported for Sep 30 · net -1.5K sh shares · +2 new
Insider flow Distributing
Net -$533.5K over 90 days · 100% sells
Short interest Rising
5.63% of float · ▲ +36.3% MoM · 7.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
811 holders — mid 3-yr range
Squeeze score 62
elevated · 0–100
Fundamentals
Strong
Revenue growth +12%
Y/Y
Gross margin 41%
contracting
EPS growth −27%
Y/Y
Free cash flow $978.1M
Valuation P/E 34.3
below peers
Balance sheet $2.8B
net debt
Quant / Vol
risk profile
Very Low
Volatility 27%
annualized · 1-yr
Max drawdown −15%
past year
ATR 2.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 8
Latest guidance · from the 8-K filed Jul 29, 2026
Adjusted diluted earnings per share · FY 2026 Non-GAAP Initiated $2.95 – $3.05
Guided vs delivered · last 8 settled
Revenue third quarter of 2024
guided $1.55B
$1B Miss −35.2%
Diluted net earnings per share third quarter of 2024
guided $0.63 – $0.66
$0.63 In line
Revenue full year 2024
guided $6.25B – $6.3B
$4.08B Miss −35.0%
Diluted net earnings per share full year 2024
guided $2.68 – $2.74
$2.36 Miss −12.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−2% Neutral
Price vs 50-day avg
−1% Neutral
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
58% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bearish · 4 of 6
Trend (MA cross) Death cross
50d $58 › 200d $58 — 200d above 50d
Institutional flow Distributing
39 of 811 funds reported for Sep 30 · net -1.5K sh shares · +2 new
Insider flow Distributing
Net -$533.5K over 90 days · 100% sells
Short interest Rising
5.63% of float · ▲ +36.3% MoM · 7.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
811 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $48 Now $57 · 58% Range high $64
vs 200-day avg -2% vs 50-day avg -1% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Scientific & Technical Instruments — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FTV
Fortive Corp
this stock
$17.46B +3.7% +12.1% 34.3 5.6%
KEYS
Keysight Technologies, Inc.
$65.16B +88.4% +8.0% 52.4 1.4%
COHR
Coherent Corp.
$61.22B +69.4% +19.2% 75.9 5.6%
GRMN
Garmin Ltd
$51.75B +32.3% +15.1% 30.0 1.7%
TDY
Teledyne Technologies Inc
$28.45B +20.2% -4.6% 29.7 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
811
% held
108.3%
Reported
39 of 811
Top holder
Dodge & Cox
Held Float
View
Held by Funds
Fund positions
675
View
Short & Settlement
Short Interest Rising
Shares short
17.2M
Days to cover
7.9d
Change
+4.6M sh
View
Short Volume
Short vol %
71%
As of
Oct 9, 2026
Short Total
View
Fails to Deliver
FTD shares
2
Value
$114
As of
Sep 8, 2026
View
Off-Exchange
Off-exchange %
33.6%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$533.5K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$4.2B
Net income (FY)
$579.2M
EPS diluted
$1.73
View
Buybacks
Remaining
shares 17.7M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 15, 2026
This year
14
View
Proposed Sales
Value
$533.5K
Shares
8.7K
Filed
Aug 10, 2026
View
Exempt Offerings
Offering
Indefinite
Filed
Mar 3, 2020
View
Earnings & Events
Webcasts Upcoming
Next webcast
Oct 28, 2026
Last webcast
Sep 15, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
FTV -0.4% +4.7% -6.1% +4.5% +3.7%
SPY +1.2% +1.9% +9.9% +2.1% +14.2%
vs SPY -1.5% +2.8% -15.9% +2.4% -10.5%

Capital returns

Latest dividend
$0.07 / share · ex Sep 4, 2026
Raised 16.7%
Paid (TTM)
$0.25 / share · 4 payouts
Dividend yield (TTM, derived)
0.44%
Buyback program · as of Jul 3, 2026
Authorized
—
Spent (derived)
—
Remaining
shares 17.70M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1659166 CUSIP 34959J108 13F (30d) 57 filings 44 filers Visit website Investor relations